Last reviewed · How we verify
Lysozyme hydrochloride
Lysozyme hydrochloride is a Antimicrobial enzyme Small molecule drug developed by Eisai Co., Ltd.. It is currently FDA-approved for Bacterial infections (topical/local use), Dry eye syndrome (as a component of tear substitutes).
Lysozyme hydrochloride is an antimicrobial enzyme that breaks down bacterial cell walls by cleaving peptidoglycan, thereby killing bacteria and reducing infection.
Lysozyme hydrochloride is an antimicrobial enzyme that breaks down bacterial cell walls by cleaving peptidoglycan, thereby killing bacteria and reducing infection. Used for Bacterial infections (topical or systemic use), Dry eye syndrome (xerophthalmia).
At a glance
| Generic name | Lysozyme hydrochloride |
|---|---|
| Sponsor | Eisai Co., Ltd. |
| Drug class | Antimicrobial enzyme |
| Target | Peptidoglycan (bacterial cell wall component) |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
Lysozyme is a naturally occurring enzyme that catalyzes the hydrolysis of β-1,4 glycosidic bonds in peptidoglycan, a major structural component of bacterial cell walls. This enzymatic degradation compromises bacterial cell wall integrity, leading to cell lysis and death. The drug is used topically or locally to provide antimicrobial activity against susceptible bacteria.
Approved indications
- Bacterial infections (topical/local use)
- Dry eye syndrome (as a component of tear substitutes)
Common side effects
- Local irritation or burning at application site
- Allergic reactions
Key clinical trials
- Efficacy and Safety of the Lysobact Complete Spray®, Tantum Verde® and Pharyngal® Oromucosal Spray in the Treatment of Acute Sore Throat (PHASE3)
- Effects of Lysozyme on Acute Exacerbation of Chronic Obstructive Pulmonary Disease : A Randomised Placebo-Controlled Study (PHASE4)
- Pharmacological Effect of Lysozyme for Chronic Obstructive Pulmonary Disease and Asthma With Sputum Symptom (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Lysozyme hydrochloride CI brief — competitive landscape report
- Lysozyme hydrochloride updates RSS · CI watch RSS
- Eisai Co., Ltd. portfolio CI
Frequently asked questions about Lysozyme hydrochloride
What is Lysozyme hydrochloride?
How does Lysozyme hydrochloride work?
What is Lysozyme hydrochloride used for?
Who makes Lysozyme hydrochloride?
What drug class is Lysozyme hydrochloride in?
What development phase is Lysozyme hydrochloride in?
What are the side effects of Lysozyme hydrochloride?
What does Lysozyme hydrochloride target?
Related
- Drug class: All Antimicrobial enzyme drugs
- Target: All drugs targeting Peptidoglycan (bacterial cell wall component)
- Manufacturer: Eisai Co., Ltd. — full pipeline
- Therapeutic area: All drugs in Infectious Disease
- Indication: Drugs for Bacterial infections (topical/local use)
- Indication: Drugs for Dry eye syndrome (as a component of tear substitutes)
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing